Glycosylation is one of the most common post-translational modifications of proteins. It is estimated that over half of mammalian proteins are glycosylated. Patients with several autoimmune disorders, chronic inflammatory diseases, and some infectious diseases exhibit abnormal glycosylation of serum immunoglobulins and other glycoproteins (1-5). The biological functions of these modifications in health and disease have become a significant area of interest in biomedical research (6). A subset of these glycoproteins has clustered sites of O-glycosylation with serine-and threonine-rich stretches within the amino acid sequence. Mucins, such as membrane-associated MUC1, are perhaps the best known family of proteins that are heavily O-glycosylated. Their altered expression and aberrant glycosylation have made them potential targets as biomarkers for early detection of cancer (7). Immunoglobulin A1 (IgA1) 1 contains both O-and N-glycans (Fig. 1) . Aberrant O-glycosylation of IgA1 is involved in the pathogenesis of IgA nephropathy (IgAN) and the closely related Henoch-Schö nlein purpura nephritis (1, 8). Interestingly, the aberrantly glycosylated molecules, IgA1 in IgAN and MUC1 in cancer, are recognized by the immune system as neoepitopes as evidenced by formation of specific antibodies (9 -11). Mucin-like bacterial surface proteins exhibit similar properties: the molecules have clustered bacterial O-glycans that mediate cellular adhesion, and blocking antibodies target these glycan-containing epitopes (12).
Glycosylation is one of the most common post-translational modifications of proteins. It is estimated that over half of mammalian proteins are glycosylated. Patients with several autoimmune disorders, chronic inflammatory diseases, and some infectious diseases exhibit abnormal glycosylation of serum immunoglobulins and other glycoproteins (1) (2) (3) (4) (5) . The biological functions of these modifications in health and disease have become a significant area of interest in biomedical research (6) . A subset of these glycoproteins has clustered sites of O-glycosylation with serine-and threonine-rich stretches within the amino acid sequence. Mucins, such as membrane-associated MUC1, are perhaps the best known family of proteins that are heavily O-glycosylated. Their altered expression and aberrant glycosylation have made them potential targets as biomarkers for early detection of cancer (7) . Immunoglobulin A1 (IgA1) 1 contains both O-and N-glycans ( Fig. 1) . Aberrant O-glycosylation of IgA1 is involved in the pathogenesis of IgA nephropathy (IgAN) and the closely related Henoch-Schö nlein purpura nephritis (1, 8) . Interestingly, the aberrantly glycosylated molecules, IgA1 in IgAN and MUC1 in cancer, are recognized by the immune system as neoepitopes as evidenced by formation of specific antibodies (9 -11) . Mucin-like bacterial surface proteins exhibit similar properties: the molecules have clustered bacterial O-glycans that mediate cellular adhesion, and blocking antibodies target these glycan-containing epitopes (12) .
An O-glycosylated protein from a single source contains a population of variably O-glycosylated isoforms that show a distinct distribution of microheterogeneity of the O-glycan chains in terms of number, sites of attachment, and composition. Characterizing these clustered sites and understanding how the distributions change under different biological conditions or disease states are an analytical challenge. Enzymatic or chemical release of O-glycans is not selective. The heterogeneity, composition, and quantitative aspects of different O-glycan chains can be assessed and quantified by gas chromatographic and/or mass spectrometric techniques.
However, the site-specific information and context of location and composition of adjacent chains are lost. Carbohydratespecific lectin analysis of O-glycoproteins can provide information on glycan composition and comparative differences between samples, such as those from healthy controls and patients with various disease states. We have successfully demonstrated this in the analysis of IgA1 O-glycans from patients with IgAN versus healthy controls and disease controls (13) (14) (15) . This included proximal assessment of sites with galactose (Gal)-deficient O-glycans after digests with IgAspecific proteases (8) . Several studies have demonstrated the value of mass spectrometry (MS) in identifying Gal-deficient IgA1 in patients with IgAN (16 -21) , including our work that demonstrated the first direct localization of native sites of O-glycan chains in the hinge region (HR) of IgA1 by use of electron capture dissociation (ECD) (20, 22) . ECD and the more recently developed electron transfer dissociation (ETD) have been used to identify sites of O-glycosylation on a variety of proteins (23) (24) (25) (26) . This includes the analysis of sites of O-glycosylation by on-line LC-ECD/ETD MS/MS methods (23, 26, 27) .
IgAN is the most common primary glomerulonephritis worldwide (28) with about 20 -40% of patients developing end stage renal failure. It is characterized by mesangial deposits of IgA1-containing immune complexes (28) . The distinctive O-glycan chains of IgA1 molecules play a pivotal role in the pathogenesis of IgAN (1, 10, 14 -16, 29, 30) . IgA1 contains an HR between the first and second heavy chain constant region domains with a high content of Ser, Thr, and Pro. This segment usually has three to five O-glycan chains per HR (31) (see Fig. 1 ). Aberrantly glycosylated IgA1, deficient in Gal in some of the O-glycans in the HR, in serum is rare in healthy individuals but is present at elevated levels in IgAN patients (13, 15) . This distinctive IgA1 is in circulating immune complexes (8, 10, 15) and in the glomerular deposits of IgAN patients (16, 29) . The absence of Gal apparently leads to the exposure of neoepitopes, including terminal and sialylated N-acetylgalactosamine (GalNAc) residues (9, 10) . These epitopes are recognized by naturally occurring antiglycan IgG or IgA1 antibodies and, consequently, circulating immune complexes are formed (9, 10, 15) that can deposit in the glomerular mesangia. To identify the pathogenic forms of IgA1, a thorough analysis of O-glycan microheterogeneity, including identification of the attachment sites, will be required.
In this work, we demonstrate the complete analysis of O-glycoform microheterogeneity and site localization of the glycoforms in a naturally Gal-deficient IgA1 (Ale) myeloma protein that mimics the nephritogenic IgA1 in patients with IgAN (8, 9) . Reversed phase (RP) LC FT-ICR MS successfully identified 10 distinct IgA1 HR fragments representing Ͼ99% of total IgA1. AI-ECD of the six most abundant IgA1 HR glycoforms (Ͼ95% of total IgA1) was accomplished with three distinct IgA-specific protease ϩ trypsin digestions, identifying sites of Gal deficiency across four distinct IgA1 O-glycoforms. Based on the success of the ECD fragmentation of these IgA1 HR fragments, we adapted the analysis for on-line LC-MS/MS methods for both ECD and ETD. The variety of IgA1 HR proteolytic fragments provides a practical set of guidelines for the ECD/ETD analysis of clustered sites of O-glycosylation on this and other proteins. These results also provide insight into the order of attachment of the O-glycans in the IgA1 HR.
EXPERIMENTAL PROCEDURES
Sample Preparation-This study was approved by the Institutional Review Board of the University of Alabama at Birmingham. The polymeric form of IgA1 myeloma protein (Ale) was previously isolated from plasma of a patient with multiple myeloma (14) . Briefly, the plasma sample was precipitated with ammonium sulfate (50% saturation) and dissolved in phosphate buffer, and IgG and IgM were removed by affinity chromatography with protein G and anti-human IgM antibodies, respectively (32) . Next, size-exclusion chromatography on a column of Ultrogel AcA22 (Amersham Biosciences) was used to isolate IgA1. The final purification step included FPLC separation of the polymeric form of IgA1 on a column of Sephacryl 300. The purity of the IgA1 preparation was assessed by SDS-PAGE, Western blotting, and ELISA using polyvalent reagents against IgA and IgG (Jackson ImmunoResearch Laboratories, West Grove, PA) and IgA1-specific and IgA2-specific monoclonal antibodies (15, 32) . The polymeric molecular form of the IgA1 (Ale) was assessed by size exclusion chromatography, nonreducing SDS-PAGE, and Western blots developed with anti-IgA antibody. The resultant preparation was polymeric IgA1 that was Gal-deficient in O-glycans, mimicking the glycosylation aberrancy of serum IgA1 in patients with IgAN (8 -10, 13-15, 32) .
Purified IgA1 protein was treated with an IgA-specific protease from Clostridium ramosum strain AK183 (recombinant in Escherichia coli), Streptococcus pneumoniae strain TIGR4 (recombinant in E. coli), Haemophilus influenzae HK50, Neisseria meningitides strain HF13 (recombinant in E. coli), or N. meningitides strain HF48 followed by trypsin to release IgA1 HR glycopeptides. The digestion with each IgA-specific protease was performed for 24 h at 37°C in PBS, pH 7.4. Then, trypsin was added and incubated for another 24 h at 37°C in 100 mM NH 4 , was prepared by two IgAspecific proteases (AK183 and HF48). Prior to analysis, these digests were treated with 10 milliunits/ml neuraminidase to remove sialic acid residues from the O-glycan chains. After sequential treatment with IgA-specific protease and trypsin, the preparations were reduced with 5 mM dithiothreitol (DTT). Half of each digest was alkylated with 10 mM iodoacetamide. For off-line microscale separation, 25 g of digested IgA1 was fractionated by RP LC (Agilent 1100 capillary pump) using a 300-m ϫ 15-cm C 18 PepMap column (LC Packings, Sunnyvale, CA) as described previously (22, 33) . Eluted IgA1 HR glycopeptides were collected as 5-l fractions in a 96-well plate by use of an Agilent 1100 microwell plate fraction collector.
On-line LC ESI FT-ICR MS Analyses-On-line LC was performed by use of an Eksigent MicroAS autosampler and 2D LC nanopump (Eksigent, Dublin, CA). Three-hundred nanograms of digested IgA1 was loaded onto a 100-m-diameter, 11-cm-long column pulled tip packed with Jupiter 5-m C 18 reversed phase beads (Phenomenex). The digests were then eluted with an acetonitrile gradient from 5 to 30% in 0.1% formic acid over 50 min at 650 nl min
Ϫ1
. Linear quad-rupole ion trap (LTQ) FT-ICR parameters were set as described previously (22) . The mass spectrometer alternated between a full FT MS scan (m/z 400 -2,000) and four subsequent MS/MS scans of the four most abundant precursor ions. Survey scans were acquired in the ICR cell with a resolving power of 100,000 at m/z 400. Precursor ions were isolated and subjected to CID in the linear ion trap as confirmation of O-glycopeptide precursor ions. Isolation width was m/z 2. Automatic gain control (AGC) was used to accumulate sufficient precursor ions (target value, 5 ϫ 10 4 ions; maximum fill period, 250 ms). Dynamic exclusion was enabled with the exclusion window set to 5 ppm with an exclusion time of 120 s after a repeat count of 3 within 60 s. Each analysis of IgA-specific protease ϩ trypsin preparations of IgA1 HR to obtain relative distribution analysis of IgA1 HR O-glycoforms was performed in triplicate with two unique preparations.
AI-ECD FT-ICR MS/MS and ETD LTQ FT MS/MS
Analysis-Off line-fractionated IgA1 HR glycopeptides were analyzed by use of a LTQ 7-tesla FT-ICR (LTQ FT) mass spectrometer or an LTQ XL with ETD mass spectrometer (Thermo Fisher Scientific, San Jose, CA). A monolithic silicon microchip-based electrospray interface, TriVersa TM NanoMate (Advion, Ithaca, NY), served as the source for electrospray ionization of the off line-fractionated IgA1 HR O-glycopeptides. AI-ECD FT-ICR MS/MS analysis was performed as described with some modifications (22) . The isolation width was m/z 10 with an AGC target value of 2 ϫ 10 6 and maximal fill period of 3,500 ms. Following transfer to the ICR cell, precursor ion populations were photonirradiated for 100 ms at 10% (2-Watt) laser power. After 100 ms of photon irradiation, the precursor populations were irradiated with the electrons for 100 ms at 2-3% energy (Ϸ0.5 eV). Each AI-ECD scan was acquired as an FT-ICR broadband mass spectrum (100 Ͻ m/z Ͻ 3,000) at a mass resolving power of 100,000 at m/z 400. Each displayed spectrum represented a sum of 100 scans. For ETD LTQ XL MS/MS experiments of off-line fractionated IgA1 HR glycopeptides, a range of ETD parameters was tested to optimize fragmentation, and the data were compared with results derived from AI-ECD LTQ FT MS/MS for the same IgA1 HR O-glycoforms. Varied parameters included inclusion of supplemental activation (SA) or not, inclusion of CID of the charge-reduced species (34) , and settings for the anion (fluoranthene) injection time (50 -500 ms). AGC was set to 1 ϫ 10 4 for analyte cations and 1.5 ϫ 10 5 for fluoranthene anions. On-line ECD/ETD Analysis-On-line LC AI-ECD FT-ICR MS/MS analysis was performed by combining the LC-MS conditions with the off-line AI-ECD FT-ICR MS/MS analysis described above with modifications. The HR O-glycopeptides were eluted with an acetonitrile gradient from 2 to 10% in 0.1% formic acid over 45 min at 650 nl min
Ϫ1
. The isolation width was m/z 7 with an AGC target value of 1 ϫ 10 6 and maximal fill period of 1,000 ms. Dynamic exclusion parameters were set as described by Creese and Cooper (35) .
For on-line LC ETD SA LTQ XL MS/MS analysis, samples were analyzed as reported previously (36) with the exception that the elution gradient was changed to 2-10% over 30 min. AGC was set as above, the analyte injection time was set to 125 ms, and the isolation window was m/z 4 with a repeat count set of 4 within 45 s.
Lectin Western Blot-Samples of IgA1 (Ale) myeloma protein were digested with a single protease at a time (8) and then separated under reducing conditions by SDS-PAGE. The blots were developed with a GalNAc-specific lectin from Helix aspersa (HAA; Sigma-Aldrich) (14) .
Data Analysis-All spectra were analyzed by use of the Xcalibur Qual Browser 2.0 software (Thermo Fisher Scientific). Individual IgA1 O-glycopeptides were identified as described previously (22) . IgA1 O-glycopeptides species in each LC-MS analysis were identified from the known sequence of the isolated HR glycopeptides, calculated monoisotopic mass of glycopeptides, and the presence of adjacent HR glycopeptides within the high resolution FT-ICR MS spectra. Monoisotopic m/z values for the IgA1 O-glycopeptides were manually tabulated from the raw data files by use of Xcalibur Qual Browser 2.0. The minimal threshold for IgA1 HR glycopeptide identification and relative abundance measurements was a signal to noise ratio of at least 5:1 with Ͼ4 isotopic peaks. Identified IgA1 HR O-glycopeptides were checked against theoretical values by use of the GlycoMod tool (http://www.expasy.org). Known IgA1 HR amino acid sequences based on the combination of IgA-specific protease ϩ trypsin digestions performed were inputted with trypsin enzyme and zero missed cleavage sites. Hexose, N-acetylhexosamine, and N-acetylneuraminic acid (NeuAc) monosaccharide residues were all selected as possible (variable) additions to the IgA HR peptides with a mass tolerance of 10 ppm. For alkylated IgA1 HR preparations, cysteine iodoacetamide modification was selected. The relative abundance of each glycopeptide was calculated by use of a label-free quantification method described by Rebecchi et al. (37) . After assigning all glycopeptide peaks in the spectrum, the ion chromatogram for each glycopeptide ion was individually extracted for the specific glycopeptide ion species Ϯ0.83 m/z. Then the total ion current from the extracted ion chromatogram of each glycopeptide was divided by the total ion current for all glycopeptides of a given charge state. The relative abundance of each differentially glycosylated IgA1 HR peptide set (IgA-specific protease ϩ trypsin) was calculated as a percentage against total glycopeptides detected. LC-MS replicate runs and differential digestions served as internal controls for assignments of relative abundance. Reported relative abundance measurements for the IgA1 HR glycopeptides in Table I are the average of four independent LC FT-ICR MS analyses of two IgA-specific protease ϩ trypsin digests. For the Thr 228 -Arg 245 C-terminal HR protease-generated fragments, a disaccharide is assumed (Ͼ97%; see supplemental Table 1 
RESULTS

Proteolytic Release and High Resolution MS Analysis of IgA1 HR Glycopeptides-To provide a variety of IgA1 HR
O-glycopeptides for analysis by LC-MS and ECD fragmentation, 50 g of IgA1 (Ale) myeloma protein was digested with three bacterial IgA-specific proteases, one at a time ( Fig. 1) , followed by trypsin. The digests, with the released series of O-glycopeptides (Table I and supplemental Table 1 ), were then subjected to on-line LC ESI FT-ICR MS or off-line RP C 18 fractionation followed by AI-ECD FT-ICR MS/MS analysis. Three-hundred nanograms of IgA1 was sufficient for on-line LC ESI FT-ICR MS analysis. Fig. 2 (22) . The assignments of hexose and N-acetylhexosamine residues as Gal and GalNAc, respectively, were based on previous glycan compositional analysis (9, 22) . Locating O-Glycan Attachment Sites-IgA1 HR released by each of the IgA-specific protease ϩ trypsin digestions was isolated using off-line RP C 18 LC fractionation (22 Fig. 4 . AI-ECD FT-ICR MS/MS spectra for the six most abundant IgA1 HR O-glycoforms are provided in the supplemental data. The combined AI-ECD analyses and relative abundance analysis (Table I) represent Ͼ95% of the total IgA1 in the sample with a defined micro-(amino acid attachment level) and macroheterogeneity (types of glycopeptides in the mixture).
On-line ECD and ETD Analysis-Based on our compiled AI-ECD analysis with different IgA1 HR fragments, we adapted an on-line LC AI-ECD FT-ICR MS/MS method from our LC FT-ICR MS profiling (22) and an LC ECD MS/MS method reported by Creese and Cooper (35) spectrometer. Pilot experiments with an off line-isolated IgA1 HR tryptic fragment, His 208 -Arg 245 , confirmed that ETD fragmentation required SA for dissociation as was the case for ECD fragmentation (20) (supplemental Fig. 2) . ETD fragmentation of His 208 -Arg 245 did not produce fragments within the clustered sites of O-glycosylation just as we previously saw with ECD of the same IgA1 HR fragment (22) and was recently reported by Wada et al. (38) , thereby suggesting that the mechanism of fragmentation was essentially the same. After a similar series of runs to optimize ETD conditions, LC-ETD SA LTQ MS/MS analysis of the IgA-specific protease-trypsin fragments produced fragmentation that was successful in locating the sites of O-glycosylation as was true for AI-ECD MS/MS (supplemental Fig. 3 ). Fig. 5 shows a comparison between the fragments observed by use of NanoMate ESI AI-ECD, LC AI-ECD, and LC ETD for the Val 222 -Arg 245 ϩ (GalNAc) 4 Gal 3 HR. Under optimized conditions for on-line LC MS/MS analysis, the IgA1 O-glycoform was isolated as a 4ϩ ion species. More ECD/ETD fragments were observed within the cluster of O-glycan sites compared with off-line preparations of the same peptide. Fig. 5B compares individual ECD/ ETD fragments from the off-line and on-line approaches for analyzing these sites of clustered O-glycans and demonstrates the improved fragmentation with the 4ϩ ion species and considerably less starting material for the analysis (10 g versus 400 ng).
Defining Overall Microheterogeneity of IgA1 O-GlycansFor most O-glycoforms of IgA1 (Ale) myeloma protein, the microheterogeneity of each site is well defined by our results (Fig. 6) 236 . Lectin Western blot analysis with GalNAc-specific lectin (HAA) of IgA1 after digestion with IgA-specific proteases supports the interpretation that these two sites are the dominant sites of Gal deficiency as deduced from the split HAA reactivity between the Fc and Fd fragments for the HK50 and HF13 digestions (Fig. 6B ). These two sites together represented Ͼ50% of Gal-deficient O-glycosylated IgA1 HR species within the sample. In summary, these results identify Ͼ99% of the total IgA1 O-glycoforms in the sample (Table I and  supplemental Table 1 ) and define the site-specific microheterogeneity of Ͼ95% (six most abundant glycoforms, five sites of glycosylation) of the total IgA1 (Ale) myeloma protein. For the six most abundant glycoforms, our analysis provides the complete amino acid context of each O-glycoform.
DISCUSSION
IgA1 myeloma proteins frequently exhibit a high abundance of Gal-deficient O-glycans similar to those on nephritogenic IgA1 in patients with IgAN (8 -10, 13-15), and because they are readily available in large amounts, they serve as convenient model proteins. Our combined ECD localization and accurate mass profiles of IgA1 HR O-glycan microheterogeneity provide a full scale picture of the range of IgA1 O-glycoforms isolated from a single source (polymeric IgA1 myeloma protein) (20, 22) . In our previous experiments, we observed certain IgA1 O-glycoforms for which we and others (38) fragments, we reasoned that it would be only a small contribution to the total population of Gal-deficient sites as supported by lectin Western blot analysis (Fig. 6B) . In all LC-MS analyses, there was no indication of loss of GalNAc or Gal residues in the ionization process. Comparison of total ion current values for these N-terminal fragments with those for their C-terminal counterparts suggests that the ionization efficiencies for the N-terminal fragments may be considerably higher, thus increasing the sensitivity for these low abundance glycoforms. Additionally, three minor His 208 -Pro 231 glycopeptides with (GalNAc) 3 Gal 1 , (GalNAc) 2 Gal 2 , and (GalNAc) 2 Gal 1 attached were also observed. The results from both N-terminal HR peptides support the existence of a small population of underglycosylated and Gal-deficient O-glycoforms N-terminal to Ser 232 . This finding means that the dominant IgA1 Oglycoforms in the C-terminal HR fragments could include low abundance mixtures of equally glycosylated isobaric forms. We have previously demonstrated that AI-ECD of IgA1 HR distinguished between a single population and an isobaric mixture of differentially glycosylated HR peptides (20) . However, fragmentation by use of ECD is less efficient than the more traditional collision-induced dissociation in the conversion of parent ions to fragments (ϳ30 versus Ͼ70% conversion) (40) . As such, a small subpopulation of isobaric IgA1 HR O-glycoforms with sites of Gal deficiency as indicated by the N-terminal fragments would not be observed in the presence of a dominant single population. Our relative quantitation of the IgA1 HR O-glycoform distributions was generated from three independent IgA-specific protease ϩ trypsin digestions. The distributions observed for each HR proteasegenerated fragment corroborate and provide an internal check for the assigned relative distributions. Heterogeneity of clustered O-glycans requires definition of microheterogeneity of individual amino acid attachment sites and of the adjacent O-glycans to provide a full scope of the distribution. Cross-validation between differentially digested HR fragments makes this possible.
We propose that the distribution of IgA1 (Ale) myeloma protein O-glycosylation is dominated by a collection of IgA1 O-glycoforms that may originate from semiordered carbohydrate additions that proceed from Thr 225 to Thr 236 . There also exists a smaller subpopulation of IgA1 O-glycoforms that does not follow this semiordered carbohydrate addition, giving rise to differentially O-glycosylated isobaric species. Wandall et al. (41) reported that the lectin domains of different GalNAc-transferases can recognize the same substrate. This could result in different sites or order of GalNAc attachment catalyzed by several GalNAc-transferases. Alternatively, there may be a low level natural occurrence of Thr 225 being "skipped" by the GalNAc-transferase enzyme. Either explanation is plausible.
The distribution of HR glycoforms for this IgA1 myeloma protein centers around the glycopeptides with (GalNAc) 4 Gal 3 , (GalNAc) 4 Gal 4 , and (GalNAc) 5 Gal 4 , similar to our previously reported IgA1 (Mce) myeloma protein and that of serum nephritogenic IgA1 (17, 18) . The assigned sites of glycosylation suggest a semiordered addition proceeding from the Thr 225 site. We propose that the (GalNAc) 4 Gal 4 IgA1 HR species is the product of the addition of a Gal residue to the GalNAc monosaccharide at Ser 230 of the (GalNAc) 4 Gal 3 IgA O-glycoform. Alternatively, but to a lesser extent, a GalNAc-transferase can add a single GalNAc monosaccharide to Thr 236 , giving rise to the (GalNAc) 5 Gal 3 IgA1 O-glycoform. Working in the opposite direction, the (GalNAc) 4 Gal 3 IgA1 O-glycoform is the product of the addition of a Gal to the Thr 228 of the (GalNAc) 4 Gal 2 IgA1 O-glycoform or, to a lesser extent, the addition of a GalNAc residue to Ser 230 to the low abundance (GalNAc) 3 Gal 3 . Based on the relative abundance, the former is the more likely route, and the (GalNAc) 4 Gal 2 O-glycoform is alternatively the substrate for addition of a GalNAc residue to Thr 236 . Therefore, the GalNAc-transferase is proceeding "ahead" of the Gal-transferase, adding GalNAc residues to Thr 225 first and then Thr 228 followed by Ser 230 and Ser 232 in some order, then by Thr 236 , and finally by a sixth undetermined site. The Gal-transferase in tandem appears to add Gal residues to the GalNAc residues first to Thr 225 followed by Ser 232 at a nearly equal rate but then lags behind slightly for the attachment at Thr 228 and even more so at Ser 230 and Thr
236
, thereby accounting for the predominant sites of Gal deficiency. (Table II) provides a unique combination of fragments to consider fundamental aspects of ECD/ETD fragmentation techniques analyzing clustered O-glycans. In our previous (20, 22) ). In our current results, the combined IgA-specific protease ϩ trypsin digestions generated IgA1 HR * Proteolytically generated fragments previously analyzed from other myeloma proteins (20, 22) .
Application of ECD/ETD to Clustered Sites of O-Glycosylation-Our collection of IgA1 HR fragments
† ECD MS/MS spectra of the IgA1 HR N-terminal peptides are provided in supplemental Fig. 4 .
fragments with the C-terminal Arg 245 and His 243 residues and a varied N terminus, depending on the IgA-specific protease. Loss of carbohydrate residues was observed for these fragments ( Fig. 3 Fig. 4 ) with an N-terminal histidine and one or two pairs of adjacent prolines resulted in a series of ambiguous c, z, and y fragments with and without carbohydrate residues.
The success of ECD/ETD peptide fragmentation with higher charge state peptide ions is well established (42, 44) . Broader studies on peptide and glycopeptide ETD fragmentation have indicated that peptide charge density (residues per charge) plays a significant role in the amount of backbone fragmentation (45, 46) . The difference in observed fragments for the 3 ϩ and 4
ϩ charged Val 222 -Arg 245 IgA1 HR peptides demonstrates this principle for improving ETD/ECD fragmentation in the analysis of clustered sites of O-glycans as well. Clustered O-glycans significantly increase the m/z of precursor cations, thus lowering the charge density. The consistent requirement for supplemental activation in our current and previous studies (20, 22) of IgA1 O-glycopeptides corroborates broader observations on its use to disrupt non-covalent interactions after ECD/ETD and increase the fragmentation efficiency of higher charge state precursor cations (45, 47) . Several groups have also reported the use of different proteases to change the relative location of the charge within peptides to optimize ECD/ETD peptide fragmentation (44, 48) . There have also been studies on the chemical modification of side chains or C termini to produce higher charge state peptides (49) . The IgA1 HR contains two cysteine residues that provide the opportunity to increase charge density in future studies. In our analysis, the proximity of the sites of proton attachment and subsequent electron capture/transfer seems to also play a role in the success of locating clustered sites of O-glycosylation and not just an indiscriminate charge density. This also has been reported in broader studies for doubly charged precursor peptide cations (50) . However, the bias is said to decrease with higher charge states. The IgA-specific protease ϩ trypsin fragments do produce lower m/z (i.e., higher charge density) glycopeptides compared with the (Fig. 5) , the O-glycopeptide fragments were recognized by mass and isotope patterns especially with on-line LC AI-ECD FT-ICR MS/ MS. For LC ETD SA LTQ XL MS/MS, the lower resolution tandem MS scans rendered assignment of the distinguishing fragments difficult. We presume that a similar analysis with a high resolution LTQ Orbitrap would improve these results as others have shown for O-glycosylation (23) . We also observed a greater frequency of hydrogen migration in the ETD with SA.
Our AI-ECD method included ion activation by low power infrared multiphoton dissociation prior to electron irradiation (22) and that may explain the observed differences (51, 52) . Comparison of on-line ECD fragmentation with ETD fragmentation of the IgA-specific protease-trypsin HR segments showed that fragment ions outside the cluster of O-glycan attachment sites were readily identified in all glycoforms as was observed with the His 208 -Arg 245 segment (supplemental Fig. 2) . Within the clustered region, ECD/ETD fragmentation of the IgA-specific protease trypsin fragments was more successful than that of the longer tryptic fragments at defining the sites of disaccharide composition and sites that were Gal-deficient. Several more z and even y fragments were observed in the NanoMate ESI AI-ECD MS/MS analysis for the Ser 240 -Arg 245 region of the HR. This finding is most likely attributable to the higher number of scans (n ϭ 80 -100) due to using larger amounts of starting material and an off-line preparation. Results for on-line AI-ECD and ETD with SA were derived from seven or fewer scans.
Implications for IgAN-IgA1 (Ale) and other IgA1 myeloma proteins mimic the Gal-deficient IgA1 in the serum of patients with IgAN as we have demonstrated in previous studies (8 -10, 13-15) . This IgA1 (Ale) myeloma protein is polymeric and Gal-deficient, reacts with glycan-specific antibodies from sera of IgAN patients, and forms immune complexes that can activate cultured mesangial cells (8, 9) . 2 However, unlike the Gal-deficient IgA1 in patients with IgAN, the O-glycans of the IgA1 (Ale) myeloma protein is minimally sialylated. Our work lays the foundation for analysis of this nephritogenic IgA1 to define the frequency of the various Gal-deficient glycans and their sites of attachment on the heavy chain. There likely are different sets or classes of Gal-deficient O-glycan-dependent epitopes. These variations may reflect an aberrant activity of the specific glycosyltransferases. However the Gal-deficient species arise, a combined use of IgA-specific protease ϩ trypsin will define the O-glycan-dependent epitope recognized by circulating antibodies that subsequently lead to formation of circulating immune complexes that induce renal injury. Variations in the composition or location of the Galdeficient glycans may account for differences in the clinical severity of the disease.
Conclusions-Characterization of the molecular details of heterogeneity of the Gal-deficient O-linked glycans on serum IgA1 is vital for understanding the pathogenesis of IgAN. Each IgA1 O-glycoform represents a unique protein. In the case of IgAN, some forms are pathogenic, whereas others may not be. Comprehensive analysis of this post-translational modification requires targeted proteomics preparation engineering based on the amino acid sequence of a given protein and knowledge of how it will fragment. Our analysis of an IgA1 myeloma protein demonstrates that ECD/ETD fragmentation combined with IgA-specific protease digestion can define the distribution and specific sites of Gal deficiency for the majority of the O-glycoforms within a single sample of IgA1. Moreover, this analysis can be accomplished in an on-line LC-MS format. This work represents a significant step forward in the analysis of clustered sites of O-glycosylation. Although specific for the IgA1 HR, there is a commonality of Ser/Thr-and Pro-rich sequences in many of these clustered sites. This study lays the frame-work for successfully defining the sites of attachment, single-site and overall microheterogeneity, and O-glycoform distribution of clustered sites of O-glycosylation, such as those in immunoglobulins, mucins, and bacterial cellsurface proteins. At the same time, these results provide a means to thoroughly characterize aberrant IgA1 O-glycans that contribute to the pathology of the most common form of glomerulonephritis in the world.
